...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients
【24h】

Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients

机译:动脉内输液化疗与孤立的上腹部灌注晚期胰腺癌:454例患者的回顾性队列研究

获取原文
获取原文并翻译 | 示例

摘要

Purpose The treatment of pancreatic carcinoma remains a challenge as prognosis is poor, even if confined to a single anatomical region. A regional treatment of pancreatic cancer with high drug concentrations at the tumor site may increase response behaviour. Intra-arterial administration of drugs generates homogenous drug distribution throughout the entire tumor volume. Methods We report on treatment outcome of 454 patients with advanced pancreatic carcinoma (WHO stage III: 174 patients, WHO stage IV: 280 patients). Patients have been separated to two different treatment protocols. The first group (n = 233 patients) has been treated via angiographically placed celiac axis catheters. The second group (n = 221 patients) had upper abdominal perfusion (UAP) with stopflow balloon catheters in aorta and vena cava. Both groups have been treated with a combination of cisplatin, adriamycin and mitomycin. Results For stage III pancreatic cancer, median survival rates of 8 and 12 months were reached with IA and UAP treatment, respectively. For stage IV pancreatic cancer, median survival rates of 7 and 8.5 months were reached with IA and UAP treatment, respectively. Resolution of ascites has been reached in all cases by UAP treatment. Toxicity was generally mild, WHO grade I or II, toxicity grade III or IV was only noted in patients with severe systemic pretreatment. The techniques, survival data and detailed results are demonstrated. Conclusions Responsiveness of pancreatic cancer to regional chemotherapy is drug exposure dependent. The isolated perfusion procedure is superior to intra-arterial infusion in survival times.
机译:目的,胰腺癌的治疗仍然是挑战,因为预后差,即使被限制在单一解剖区域。肿瘤部位高药物浓度的胰腺癌的区域治疗可能增加响应行为。动脉内给药药物在整个肿瘤体内产生均匀的药物分布。方法报告454例晚期胰腺癌患者治疗结果(世卫组织III阶段:174例,世卫组织第四阶段:280名患者)。患者已分开两种不同的治疗方案。第一组(N = 233名患者)通过血管造影胸轴导管进行治疗。第二组(n = 221名患者)具有上腹部灌注(UAP),其中止血球导管在主动脉和腔静脉中。两组已经用顺铂,adriamycin和丝霉素的组合治疗。结果III阶段胰腺癌,8和12个月的中位存活率分别与IA和UAP治疗达到。对于阶段胰腺癌,分别与IA和UAP治疗达到7和8.5个月的中位存活率。通过UAP治疗,所有案例都达成了腹水的分辨率。毒性一般是轻度,世卫组织I或II级,毒性等级III或IV患者仅在严重的全身预处理的患者中注意到。证明了技术,生存数据和详细结果。结论胰腺癌对区域化疗的反应性是药物暴露依赖性。分离的灌注程序优于生存时间中动脉内输注。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号